Commercial Hepatitis B vaccine

Phase 3Vaccine

Commercial Hepatitis B vaccine is one of 73 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Commercial Hepatitis B vaccine

MMahidol University

Phase 3

1 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

SOF/VEL

Gilead

Preclinical

4 10

Pegintron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Not yet recruiting

Chronic Hepatitis B Virus Infection

NCT03038802

Clinical

Trials by Indication[1]

Chronic Hepatitis1 trial

HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg

Unknown status·MMahidol University·Phase 3·NCT03405597·97 enrolled

Chronic Hepatitis B Virus Infection1 trial

A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection

Not yet recruiting·VVaxine Pty Ltd·Phase 1/2·NCT03038802·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Commercial Hepatitis B vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Commercial Hepatitis B vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Commercial Hepatitis B vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mahidol University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: MMahidol University

Commercial Hepatitis B vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Chronic Hepatitis1 trial

Chronic Hepatitis B Virus Infection1 trial

References

Drug Info

Quick Facts

Related News